Intrinsically disordered proteins and novel strategies for drug discovery

被引:99
作者
Uversky, Vladimir N. [1 ,2 ]
机构
[1] Univ S Florida, Dept Mol Med, Coll Med, Byrd Alzheimers Res Inst, Tampa, FL 33612 USA
[2] Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia
关键词
drug target; induced folding; inhibitor; intrinsically disordered protein; protein aggregation; protein binding; protein folding; protein misfolding; protein-cloud; protein-protein interaction; rational drug design; NATIVELY UNFOLDED PROTEINS; SMALL-MOLECULE INHIBITORS; UNSTRUCTURED PROTEINS; STRUCTURAL DISORDER; ALPHA-SYNUCLEIN; NEURODEGENERATIVE-DISEASES; FUNCTIONAL ANTHOLOGY; AMYLOID FIBRILS; HUB PROTEINS; INTERACTION NETWORKS;
D O I
10.1517/17460441.2012.686489
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: There is a natural abundance of intrinsically disordered proteins or intrinsically disordered protein regions (IDPs or IDPRs), that is, biologically active proteins/regions without stable structure. Their wide functional repertoire; the ability to participate in multiple interactions; the capability to fold at binding in a template-dependent manner and their common involvement in the pathogenesis of numerous human diseases suggest that these proteins should be seriously considered as novel drug targets. Areas covered: This article describes the major classes of ordered proteins traditionally used as drug targets and introduces the molecular mechanisms of drugs targeting ordered proteins. Furthermore, it illustrates basic ways of rational drug design for these proteins, and shows why these approaches cannot be directly used for intrinsic disorder-based drug design. Some of the new approaches utilized for finding drugs targeting IDPs/IDPRs are introduced. Expert opinion: There is a continuing progress in the design of small molecules for IDPs/IDPRs and several small molecules are found that specifically inhibit the disorder-based interaction of IDPs with their numerous partners. It is expected that the initial studies will be extended and novel intrinsic disorder-based drug design approaches will be developed. Furthermore, putative new targets will be identified, and a better understanding of the molecular mechanisms underlying modulation of promiscuous IDP binding will be achieved.
引用
收藏
页码:475 / 488
页数:14
相关论文
共 137 条
[1]  
Anderson C.W., 2004, HDB CELL SIGNALING, P237
[2]  
Ashcroft F. M., 2000, ION CHANNELS DIS
[3]   Activation and activities of the p53 tumour suppressor protein [J].
Bálint, É ;
Vousden, KH .
BRITISH JOURNAL OF CANCER, 2001, 85 (12) :1813-1823
[4]   Protein-protein interactions in receptor activation and intracellular signalling [J].
Blundell, TL ;
Burke, DF ;
Chirgadze, D ;
Dhanaraj, V ;
Hyvönen, M ;
Innis, CA ;
Parisini, E ;
Pellegrini, L ;
Sayed, M ;
Sibanda, BL .
BIOLOGICAL CHEMISTRY, 2000, 381 (9-10) :955-959
[5]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[6]   Predicting protein disorder and induced folding: From theoretical principles to practical applications [J].
Bourhis, Jean M. ;
Canard, Bruno ;
Longhi, Sonia .
CURRENT PROTEIN & PEPTIDE SCIENCE, 2007, 8 (02) :135-149
[7]   A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines [J].
Chène, P ;
Fuchs, J ;
Bohn, J ;
García-Echeverría, C ;
Furet, P ;
Fabbro, D .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 299 (01) :245-253
[8]  
Chène P, 2004, MOL CANCER RES, V2, P20
[9]   Rational drug design via intrinsically disordered protein [J].
Cheng, Yugong ;
LeGall, Tanguy ;
Oldfield, Christopher J. ;
Mueller, James P. ;
Van, Ya-Yue J. ;
Romero, Pedro ;
Cortese, Marc S. ;
Uversky, Vladimir N. ;
Dunker, A. Keith .
TRENDS IN BIOTECHNOLOGY, 2006, 24 (10) :435-442
[10]   A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE [J].
CLACKSON, T ;
WELLS, JA .
SCIENCE, 1995, 267 (5196) :383-386